Edoxaban (DU-176b) + Edoxaban (DU-176b) + Edoxaban (DU-176b) + Edoxaban (DU-176b) + warfarin
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Atrial Fibrillation
Conditions
Atrial Fibrillation, Thromboembolism
Trial Timeline
Jun 1, 2007 → Jun 1, 2008
NCT ID
NCT00504556About Edoxaban (DU-176b) + Edoxaban (DU-176b) + Edoxaban (DU-176b) + Edoxaban (DU-176b) + warfarin
Edoxaban (DU-176b) + Edoxaban (DU-176b) + Edoxaban (DU-176b) + Edoxaban (DU-176b) + warfarin is a phase 2 stage product being developed by Daiichi Sankyo for Atrial Fibrillation. The current trial status is completed. This product is registered under clinical trial identifier NCT00504556. Target conditions include Atrial Fibrillation, Thromboembolism.
What happened to similar drugs?
20 of 20 similar drugs in Atrial Fibrillation were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00504556 | Phase 2 | Completed |
Competing Products
20 competing products in Atrial Fibrillation